Nucletron increases full-year outlook in light of excellent Q1 results

April 20 2011  |  Press Release 

The new outlook is based on a strong Q1 2011 

Veenendaal, the Netherlands (20 April 2011) Nucletron, a global leader in radiation oncology, today announced an updated outlook for 2011. Following strong performance in Q1 2011, Nucletron has increased its expectations for the full year. Nucletron now expects to realize double digit sales growth, while EBITDA is expected to grow by a minimum of 20% vs. 2010.

This exceeds the outlook announced in the 2010 annual results press release published March 15th 2011, in which Nucletron forecast double digit sales and profitability growth in 2011, as well as further improvement in its market position in all core markets. In 2010, sales grew by 14% to EUR 128.2 million. EBITDA increased by 26% to EUR 25.4 million over the same period. The new outlook is based on a strong Q1 2011, driven by all product lines. Sales increased by 11% in Q1 to EUR 28.9 million and EBITDA grew by 15% to EUR 4.0 million.

Jos Lamers, CEO of Nucletron, comments:  “In Q1 2011 we have continued the strong performance of 2010. We are clearly benefiting from our focused business strategy. Alongside broadening our product offering to our installed base, this strategy is based on extending the use of brachytherapy to other body sites, expanding into new geographic markets, and increasing the availability and awareness of brachytherapy. We are convinced that we can continue our strong performance in the remainder of the year.”

About Nucletron
Nucletron provides state of the art radiotherapy solutions for cancer treatment that meet the evolving needs of patients, their caregivers and healthcare professionals around the world. Nucletron has unmatched global leadership in brachytherapy, a very precise, highly effective and well-tolerated treatment option for use by healthcare providers, tailored to the needs of individual patients. We work with clinical teams to constantly improve and develop an innovative portfolio of integrated products, software and services that assures excellent patient outcomes.  Headquartered in Veenendaal, The Netherlands, Nucletron employs more than 500 employees, with offices in 18 countries, and products available in more than 100 countries around the world. Please visit http://www.nucletron.com/ to learn more about our healthcare solutions.